세계의 항체 발굴 서비스 시장 : 유형별, 숙주별, 분자별, 최종 사용자별, 지역별 예측(-2030년)

The antibody discovery services market is expected to reach 3.54 billion in 2030 from USD 1.90 billion in 2024, at a CAGR of 13.3% during the forecast period.

Factors propelling the antibody discovery services market include the development of advanced formats such as bispecific antibodies (bsAbs) and ADCs, alongside rising venture funding and strategic partnerships. Moreover, the integration of AI and adoption of end-to-end service models are streamlining workflows, enhancing efficiency, and accelerating innovation in the field.

The mice & rats segment accounted for the largest share of the antibody discovery immunization & host management services market in 2024.

The market is segmented into mice & rats, rabbits, chickens, camelids, and other hosts. In 2024, the mouse & rat segment accounted for the largest share of the antibody discovery immunization & host management services market. These species remain the preferred choice due to their genetic similarity to humans, cost-effectiveness, and highly optimized breeding and experimental protocols. Their widespread use reflects well-established immunization workflows and robust host management infrastructure in preclinical antibody discovery efforts. Furthermore, the prevalence of mouse and rat models supports scalable, reproducible immunization services, facilitating rapid antibody generation through tried-and-tested immunological methods. This segmentation also enables service providers to tailor immunization strategies and host handling practices to well-characterized animal systems, enhancing predictability and efficiency. Collectively, these advantages cement the mouse & rat host segment as the dominant segment in immunization and host management services within the antibody discovery services market.

In 2024, by end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market.

The antibody discovery services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, the pharmaceutical & biotechnology companies segment accounted for the largest share of the antibody discovery services market, driven by the scale of research and development activities directed toward therapeutic antibody programs. These companies manage extensive pipelines that require continuous discovery of new antibody candidates across oncology, immunology, infectious diseases, and other therapeutic areas. They invest heavily in advanced technologies such as phage display, hybridoma, and AI-based screening platforms provided by specialized service providers to support this. The high demand for outsourcing also reflects the need to streamline timelines, reduce internal costs, and access capabilities unavailable in-house. In addition, pharmaceutical and biotechnology firms pursue partnerships and collaborations that expand access to discovery platforms, enabling them to move efficiently from target identification to preclinical evaluation. The combination of broad therapeutic focus, large-scale investments, and reliance on external expertise established these companies as the leading contributors to market demand in 2024.

In 2024, North America accounted for the largest share of the antibody discovery services market.

North America accounted for the largest share of the antibody discovery services market in 2024. The region accounted for this position due to its concentration of pharmaceutical and biotechnology companies, research institutes, and contract service providers engaged in antibody development. Extensive funding for biomedical research from government agencies and private investors created a steady demand for discovery services. North America also benefits from a mature regulatory framework that supports the advancement of antibody-based therapeutics, enabling efficient progression from discovery to clinical evaluation. The presence of advanced research infrastructure, a skilled workforce, and established technology platforms further strengthened the region's capacity to utilize and expand antibody discovery services. In addition, high clinical trial activity and strong collaborations between industry and academia contributed to sustained demand. Collectively, these factors positioned North America as the leading region in the global antibody discovery services market in 2024.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%
• By Region: North America -45%, Europe - 20%, Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%

Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), Sino Biological, Inc. (China), Shanghai ChemPartner (China), Biocytogen (China), Samsung Biologics (South Korea), Fusion Antibodies (UK), Twist Bioscience (US), Curia Global, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), GenScript (US), Creative Biolabs (US), Viva Biotech (China), Harbour BioMed (China), ImmunoPrecise Antibodies Ltd. (Canada), Aragen Life Sciences Ltd. (India) are some of the key companies offering Antibody Discovery Services products.

Research Coverage

This research report categorizes the Antibody Discovery Services market by Type [Target Identification & Validation, Antibody Engineering & Optimization (Phage/Yeast Display Technology, Hybridoma Technology, Single-Cell Technologies, Other Technologies), Antigen Design & Production, Immunization & Host Management, Other Services], Immunization & Host Management By Host (Mice & Rats, Rabbits, Chickens, Camelids, Other Hosts), Molecule (Monoclonal Antibodies, Polyclonal Antibodies, Other Molecules), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Other End Users), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Antibody Discovery Services market. A detailed analysis of the key industry players has provided insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the antibody discovery services market. This report covers a competitive analysis of top players and upcoming startups in the Antibody Discovery Services market ecosystem.

The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Antibody Discovery Services market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the Antibody Discovery Services market. This report covers the competitive analysis of upcoming startups in the Antibody Discovery Services market ecosystem.

Key Benefits of Buying the Report

This report provides a detailed picture of the antibody discovery services market. It aims to estimate the size and future growth potential of the market across different segments such as the type, host, molecule, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.

The report provides insights into the following pointers:

Analysis of key drivers (Development of new antibody formats, growing number of ADCs in clinical trials, rising funds for venture and partnership for biologics), restraints (High cost & complexity of biologics discovery, competition from alternative modalities, patent cliffs and rise of biosimilars), opportunities (end-to-end discovery-to-IND service bundles, integration of AI and automation in discovery workflow), Challenges (reagent & raw material supply chain bottlenecks, fragmented data and workflow infrastructure)

• Service Development/Innovation: Detailed insights on newly launched Services, and technological assessment of the antibody discovery services market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the antibody discovery services market across varied regions.
• Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the antibody discovery services market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), among others in the antibody discovery services market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
• 1.4 YEARS CONSIDERED
  • 1.4.1 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary data sources
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET ESTIMATION
    • 2.2.1.1 Company revenue analysis (bottom-up approach)
    • 2.2.1.2 MnM repository analysis & primary interviews
    • 2.2.1.3 Insights from primary experts
    • 2.2.1.4 Segmental market size estimation by top-down approach
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
• 3.3 DISRUPTIVE TRENDS SHAPING ANTIBODY DISCOVERY SERVICES MARKET
• 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

4 PREMIUM INSIGHTS

• 4.1 ANTIBODY DISCOVERY SERVICES MARKET OVERVIEW
• 4.2 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE AND COUNTRY (2024)
• 4.3 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030
• 4.4 ANTIBODY DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.5 ANTIBODY DISCOVERY SERVICES MARKET SHARE, BY TYPE
• 4.6 UNMET NEEDS & WHITE SPACES
• 4.7 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
• 4.9 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
• 4.10 VC/PRIVATE EQUITY INVESTMENT TRENDS
• 4.11 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
  • 4.11.1 SUSTAINABILITY IMPACT
  • 4.11.2 REGULATORY POLICIES & ACCESS INITIATIVES
• 4.12 IP/PATENT LANDSCAPE IN ANTIBODY DISCOVERY SERVICES MARKET

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Development of bispecific antibodies and antibody fragments
    • 5.2.1.2 Rising number of antibody-drug conjugates in clinical trials
    • 5.2.1.3 Increasing venture and partnership funding for biologics
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs and complexity of biologics discovery
    • 5.2.2.2 Competition from alternative modalities
    • 5.2.2.3 Patent cliffs for blockbuster monoclonal antibodies and rise of biosimilars
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 End-to-end discovery-to-IND service bundles/one-stop shop models in antibody discovery
    • 5.2.3.2 Integration of AI and automation in discovery workflow
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Reagents and raw material supply chain bottlenecks
    • 5.2.4.2 Fragmented data and disjointed workflow infrastructure

6 INDUSTRY TRENDS

• 6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 6.2 VALUE CHAIN ANALYSIS
• 6.3 ECOSYSTEM ANALYSIS
  • 6.3.1 RAW MATERIAL SUPPLIERS
  • 6.3.2 ANTIBODY DISCOVERY SERVICE PROVIDERS
  • 6.3.3 END USERS
  • 6.3.4 REGULATORY BODIES
• 6.4 INVESTMENT & FUNDING SCENARIO
  • 6.4.1 MAJOR INVESTMENTS AND FUNDING
• 6.5 TECHNOLOGY ANALYSIS
  • 6.5.1 KEY TECHNOLOGIES
    • 6.5.1.1 Phage display platforms
    • 6.5.1.2 Hybridoma technology
    • 6.5.1.3 Single B-cell screening
  • 6.5.2 COMPLEMENTARY TECHNOLOGIES
    • 6.5.2.1 AI/ML-based protein structure prediction
    • 6.5.2.2 Surface plasmon resonance (SPR)/Bio-layer interferometry (BLI)
    • 6.5.2.3 Cryo-electron microscopy (CRYO-EM)
  • 6.5.3 ADJACENT TECHNOLOGIES
    • 6.5.3.1 CRISPR-based functional genomics
    • 6.5.3.2 CHO cell line development
    • 6.5.3.3 In-vivo modelling
• 6.6 PATENT ANALYSIS
  • 6.6.1 METHODOLOGY
  • 6.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
  • 6.6.3 LIST OF KEY PATENTS
• 6.7 KEY CONFERENCES & EVENTS, 2025-2026
• 6.8 CASE STUDY ANALYSIS
  • 6.8.1 BISPECIFIC ANTIBODY MANUFACTURABILITY ASSESSMENT AND OPTIMIZATION
  • 6.8.2 ACCELERATING ANTIBODY DISCOVERY FOR PANDEMIC PREPAREDNESS
  • 6.8.3 USE OF REPAB POLYCLONAL ANTIBODY SEQUENCING PLATFORM TO TO IDENTIFY PROTECTIVE ANTIBODIES FROM HUMAN HOSTS IMMUNE TO MALARIA
• 6.9 REGULATORY ANALYSIS
  • 6.9.1 REGULATORY LANDSCAPE
    • 6.9.1.1 North America
    • 6.9.1.2 Europe
    • 6.9.1.3 Asia Pacific
    • 6.9.1.4 Rest of the World
  • 6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 6.10 PORTER'S FIVE FORCES ANALYSIS
  • 6.10.1 BARGAINING POWER OF SUPPLIERS
  • 6.10.2 BARGAINING POWER OF BUYERS
  • 6.10.3 THREAT OF NEW ENTRANTS
  • 6.10.4 THREAT OF SUBSTITUTES
  • 6.10.5 INTENSITY OF COMPETITIVE RIVALRY
• 6.11 KEY STAKEHOLDERS & BUYING CRITERIA
  • 6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 6.11.2 KEY BUYING CRITERIA
• 6.12 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET
  • 6.12.1 INTRODUCTION
  • 6.12.2 MARKET POTENTIAL OF AI

7 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 TARGET IDENTIFICATION & VALIDATION
  • 7.2.1 INTEGRATION OF OMICS-DRIVEN INSIGHTS WITH HIGH-THROUGHPUT FUNCTIONAL VALIDATION TO PROPEL MARKET GROWTH
• 7.3 ANTIBODY ENGINEERING & OPTIMIZATION
  • 7.3.1 ANTIBODY ENGINEERING & OPTIMIZATION, BY TECHNOLOGY
    • 7.3.1.1 Phage display technology
      • 7.3.1.1.1 Adoption of AI-enhanced phage display to augment segment growth
    • 7.3.1.2 Hybridoma technology
      • 7.3.1.2.1 Advancements in automation and single-cell integration to support segment growth
    • 7.3.1.3 Single-cell technologies
      • 7.3.1.3.1 Use of high-throughput, single-cell platforms to boost segment growth
    • 7.3.1.4 Other antibody engineering & optimization technologies
• 7.4 ANTIGEN DESIGN & PRODUCTION
  • 7.4.1 HIGH-QUALITY ANTIGEN DESIGN AND PRODUCTION TO SPUR SEGMENT GROWTH
• 7.5 IMMUNIZATION & HOST MANAGEMENT
  • 7.5.1 RISING ADOPTION OF ADVANCED TRANSGENIC AND HUMANIZED MODELS TO PROPEL SEGMENT GROWTH
• 7.6 OTHER ANTIBODY DISCOVERY SERVICES

8 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST

• 8.1 INTRODUCTION
• 8.2 MOUSE & RAT
  • 8.2.1 GROWING PRECLINICAL RESEARCH DEMAND TO DRIVE GROWTH
• 8.3 RABBIT
  • 8.3.1 INCREASED RESEARCH AND DIAGNOSTIC APPLICATIONS TO FAVOR MARKET GROWTH
• 8.4 CHICKEN
  • 8.4.1 INCREASING FOCUS OF THERAPEUTIC AND DIAGNOSTIC APPLICATIONS TO DRIVE MARKET
• 8.5 CAMELIDS
  • 8.5.1 RISING ADOPTION OF NANOBODIES IN THERAPEUTICS AND DIAGNOSTICS TO BOOST MARKET GROWTH
• 8.6 OTHER HOSTS

9 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE

• 9.1 INTRODUCTION
• 9.2 MONOCLONAL ANTIBODIES
  • 9.2.1 GROWING ADOPTION IN TISSUE TYPING FOR ORGAN & BLOOD TRANSPLANTS AND PERSONALIZED MEDICINES TO DRIVE MARKET
• 9.3 POLYCLONAL ANTIBODIES
  • 9.3.1 DIVERSE EPITOPE RECOGNITION ABILITY OF POLYCLONAL ANTIBODIES TO SUPPORT SEGMENT GROWTH
• 9.4 OTHER MOLECULES

10 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 STRATEGIC COLLABORATIONS AND AI INTEGRATION TO BOLSTER GROWTH
• 10.3 ACADEMIC & RESEARCH INSTITUTES
  • 10.3.1 INCREASING COLLABORATIVE RESEARCH AND RISING GRANT FUNDING TO AUGMENT MARKET GROWTH
• 10.4 OTHER END USERS

11 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate antibody discovery services market during forecast period
  • 11.2.3 CANADA
    • 11.2.3.1 Innovative biotech community and strategic platform investments to propel market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Transformative cross-border acquisitions and platform-driven antibody innovation to expedite market growth
  • 11.3.3 UK
    • 11.3.3.1 Ramped ADC innovation and surging biotech investment to propel market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Strategic biomanufacturing investments and AI-enabled innovation to support market expansion
  • 11.3.5 ITALY
    • 11.3.5.1 Advanced R&D infrastructure and biotech innovation to aid market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 High biotech investment and innovation in advanced antibody modalities to drive market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Scalable integrated platforms, strategic global certification, and domestic innovation acceleration to augment market growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Enhanced translational platforms and strategic cross-border R&D partnerships to expedite market growth
  • 11.4.4 INDIA
    • 11.4.4.1 Advanced biomanufacturing platforms and innovation-led public-private partnerships to strengthen Indian market
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 AI platform investments and CDMO-led modality innovation to accelerate market growth
  • 11.4.6 AUSTRALIA
    • 11.4.6.1 High-throughput single-cell platforms and increased academic-industry collaborations to spur market growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Local biologics infrastructure expansion and collaborative innovation ecosystems to favor market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Focus on local emerging startups and industry-academic collaborations to aid antibody discovery services
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 UAE
      • 11.6.2.1.1 High biomanufacturing investments and focus on global pharmaceutical partnerships to fuel market growth
    • 11.6.2.2 Kingdom of Saudi Arabia
      • 11.6.2.2.1 Advanced biologics infrastructure and strategic life science innovation hubs to bolster market growth
    • 11.6.2.3 Rest of GCC Countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 ADVANCED REGIONAL MANUFACTURING CAPABILITIES AND BIOTECH INNOVATION ECOSYSTEMS TO DRIVE MARKET
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Type footprint
    • 12.5.5.4 Host footprint
    • 12.5.5.5 Molecule footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 List of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/SERVICE COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 SERVICE LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 WUXI BIOLOGICS
    • 13.1.1.1 Business overview
    • 13.1.1.2 Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
      • 13.1.1.3.2 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 THERMO FISHER SCIENTIFIC INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
      • 13.1.2.3.2 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 CHARLES RIVER LABORATORIES
    • 13.1.3.1 Business overview
    • 13.1.3.2 Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 EVOTEC
    • 13.1.4.1 Business overview
    • 13.1.4.2 Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
      • 13.1.4.3.2 Contracts
      • 13.1.4.3.3 Expansions
      • 13.1.4.3.4 Other developments
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 BIOCYTOGEN
    • 13.1.5.1 Business overview
    • 13.1.5.2 Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Service launches
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 EUROFINS SCIENTIFIC
    • 13.1.6.1 Business overview
    • 13.1.6.2 Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Expansions
  • 13.1.7 SHANGHAI CHEMPARTNER
    • 13.1.7.1 Business overview
    • 13.1.7.2 Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY'S LABORATORIES)
    • 13.1.8.1 Business overview
    • 13.1.8.2 Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Expansions
  • 13.1.9 SINO BIOLOGICAL, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Deals
      • 13.1.9.3.2 Expansions
  • 13.1.10 SAMSUNG BIOLOGICS
    • 13.1.10.1 Business overview
    • 13.1.10.2 Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Service launches
  • 13.1.11 GENSCRIPT
    • 13.1.11.1 Business overview
    • 13.1.11.2 Services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Service launches
      • 13.1.11.3.2 Deals
  • 13.1.12 CURIA GLOBAL, INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
      • 13.1.12.3.2 Other developments
  • 13.1.13 TWIST BIOSCIENCE
    • 13.1.13.1 Business overview
    • 13.1.13.2 Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Service launches
      • 13.1.13.3.2 Deals
      • 13.1.13.3.3 Expansions
  • 13.1.14 HARBOUR BIOMED
    • 13.1.14.1 Business overview
    • 13.1.14.2 Services offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Deals
      • 13.1.14.3.2 Other developments
  • 13.1.15 ARAGEN LIFE SCIENCES LTD.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Expansions
  • 13.1.16 DANAHER CORPORATION
    • 13.1.16.1 Business overview
    • 13.1.16.2 Services offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Deals
  • 13.1.17 CREATIVE BIOLABS
    • 13.1.17.1 Business overview
    • 13.1.17.2 Services offered
  • 13.1.18 VIVA BIOTECH
    • 13.1.18.1 Business overview
    • 13.1.18.2 Services offered
  • 13.1.19 IMMUNOPRECISE ANTIBODIES LTD.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Services offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Deals
  • 13.1.20 FUSION ANTIBODIES
    • 13.1.20.1 Business overview
    • 13.1.20.2 Services offered
• 13.2 OTHER PLAYERS
  • 13.2.1 ABZENA
  • 13.2.2 ALLOY THERAPEUTICS, INC.
  • 13.2.3 INTEGRAL MOLECULAR
  • 13.2.4 BIODURO
  • 13.2.5 SYNBIO TECHNOLOGIES
  • 13.2.6 ABSOLUTE ANTIBODY
  • 13.2.7 ADIMAB
  • 13.2.8 ISOGENICA
  • 13.2.9 ABLEXIS
  • 13.2.10 FAIRJOURNEY

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS